Compugen (NASDAQ:CGEN) shares rocketed 160% in morning trading Tuesday after the Israeli drug developer announced a development deal with Gilead Sciences (NASDAQ:GILD) worth up to $848M plus potential ...

Compugen (CGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one ...

A downtrend has been apparent in Compugen (CGEN) lately. While the stock has lost 10.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading ...

Compugen (NASDAQ:CGEN) stock is rocketing higher on Tuesday after announcing an exclusive licensing agreement with Gilead Sciences (NASDAQ:GILD). According to a press release from Compugen, this ...

Compugen Ltd. (NASDAQ:CGEN – Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.74 and traded as ...

Gilead Sciences Inc (NASDAQ:GILD) announced an agreement with Compugen Ltd (NASDAQ:CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the COM503 ...

Compugen Ltd.’s stock rallied by 151% on Tuesday after the company said it has agreed to sell exclusive rights to Gilead Sciences Inc. for later-stage development and commercialization of anti-IL-18 ...